The five companies being prioritized are Moderna, Johnson & Johnson, Merck, Pfizer and AstraZeneca in partnership with Oxford University. Vaccine candidates from two of these companies, Moderna and AstraZeneca, are already being tested in human subjects.
The companies will receive additional federal funding, assistance with conducting trials and manufacturing support. The federal government has prioritized these companies’ efforts in hopes its investment will expedite the process of vaccine finalization and mass production.
The HHS signed a $658 million contract June 1 with Rockville, Md.-based Emergent BioSolutions to ramp up vaccine manufacturing capacity. White House officials told The New York Times that more funding will be announced soon.
More articles on pharmacy:
Eli Lilly testing COVID-19 drug derived from survivor blood
Researchers testing several heart, anti-platelet drugs for COVID-19 patients
4 pharmacy leaders on mitigating drug shortages during a pandemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
